Vifor Fresenius gets exclusive rights to Opko's Rayaldee; Japan Rights Transferred to Vifor
Executive Summary
Vifor Fresenius Medical Care Renal Pharma Ltd. (JV between Galenica Group and Fresenius Medical Care AG; 55%-owned by Galenica) licensed exclusive global rights to develop and sell Opko Health Inc.'s Rayaldee (calcifediol), a treatment for secondary hyperparathyroidism (SHPT) in chronic kidney disease patients and also for vitamin D insufficiency. (The license excludes the US, Central and South America (excluding Mexico), Russia, China, Japan, Ukraine, Belorussia, Azerbaijan, Kazakhstan, and Taiwan.) The deal is being conducted through Opko's EirGen Pharma Ltd. subsidiary, according to an 8-K filing.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice